Francesca Toffalorio

Lorlatinib Versus Crizotinib in Patients With Advanced <i>ALK</i> -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

Benjamin Solomon, Geoffrey Liu, Enriqueta Felip et al. · Journal of Clinical Oncology · 2024 · 255 citations · Full text

Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

Benjamin Solomon, Todd M. Bauer, Tony Mok et al. · The Lancet Respiratory Medicine · 2022 · 213 citations

Oncology, Cancer Management, Open-label Crown Study +8

Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy

Paolo Andrea Zucali, Tommaso De Pas, Giovannella Palmieri et al. · Journal of Clinical Oncology · 2017 · 169 citations

Cancer Management, Thymic Carcinoma Previously, Immunology +20

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

Tommaso De Pas, Francesca Toffalorio, Michela Manzotti et al. · Journal of Thoracic Oncology · 2011 · 136 citations · Full text

Medicine, Receptor Tyrosine Kinase, Pathology +7

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs

Enriqueta Felip, Alice T. Shaw, Alessandra Bearz et al. · Annals of Oncology · 2021 · 103 citations · Full text